Tech Company Financing Transactions
Stemline Therapeutics Funding Round
On 12/31/2007, Stemline Therapeutics raised $12.5 million in financing from FirstMark Capital and private investors.
Transaction Overview
Company Name
Announced On
12/31/2007
Transaction Type
Venture Equity
Amount
$12,500,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
750 Lexington Ave. 11th Floor
New York, NY 10022
USA
New York, NY 10022
USA
Phone
Website
Email Address
Overview
Stemline Therapeutics, Inc. (NASDAQ: STML) is a clinical stage biotechnology company developing oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia and leukemia cancer stem cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ivan Bergstein
Chief Operating Officer
Kenneth Hoberman
VP - Finance
David Gionco
Browse more venture capital transactions:
Prev: 12/31/2007: Active-Semi venture capital transaction
Next: 12/31/2007: BlueStripe Software venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records on this site are derived from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs